Cargando…
Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependent
Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid‐X receptor agonist, shortened the visual evoked potential latency in patients with chronic op...
Autores principales: | McMurran, Christopher E., Mukherjee, Trisha, Brown, J William L., Michell, Andrew W., Chard, Declan T., Franklin, Robin J. M., Coles, Alasdair J., Cunniffe, Nick G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268872/ https://www.ncbi.nlm.nih.gov/pubmed/35587315 http://dx.doi.org/10.1002/acn3.51595 |
Ejemplares similares
-
Promoting remyelination in multiple sclerosis
por: Cunniffe, Nick, et al.
Publicado: (2019) -
CNS Remyelination and the Innate Immune System
por: McMurran, Christopher E., et al.
Publicado: (2016) -
Correcting gut dysbiosis can ameliorate inflammation and promote
remyelination in multiple sclerosis – No
por: McMurran, Christopher E
Publicado: (2021) -
Remyelination varies between and within lesions in multiple sclerosis following bexarotene
por: Brown, J. William L., et al.
Publicado: (2022) -
The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro
por: Gaunt, Christopher M., et al.
Publicado: (2021)